vs
Side-by-side financial comparison of Intellicheck, Inc. (IDN) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.
Relay Therapeutics, Inc. is the larger business by last-quarter revenue ($7.0M vs $6.6M, roughly 1.1× Intellicheck, Inc.). Intellicheck, Inc. produced more free cash flow last quarter ($2.4M vs $-235.9M).
Intellicheck, Inc. is a US-based technology company specializing in identity verification and fraud prevention solutions. It develops AI-powered tools to validate government-issued identification documents, streamline customer onboarding, and mitigate identity theft risks for clients across finance, retail, healthcare and public sector segments.
Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.
IDN vs RLAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.6M | $7.0M |
| Net Profit | $1.6M | — |
| Gross Margin | 91.4% | — |
| Operating Margin | 22.5% | — |
| Net Margin | 23.4% | — |
| Revenue YoY | 11.8% | — |
| Net Profit YoY | 218.0% | — |
| EPS (diluted) | $0.08 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.6M | $7.0M | ||
| Q3 25 | $6.0M | $0 | ||
| Q2 25 | $5.1M | — | ||
| Q1 25 | $4.9M | $7.7M | ||
| Q4 24 | $5.9M | $0 | ||
| Q3 24 | $4.7M | $0 | ||
| Q2 24 | $4.7M | $0 | ||
| Q1 24 | $4.7M | $10.0M |
| Q4 25 | $1.6M | — | ||
| Q3 25 | $290.0K | $-74.1M | ||
| Q2 25 | $-251.0K | — | ||
| Q1 25 | $-318.0K | $-77.1M | ||
| Q4 24 | $488.0K | — | ||
| Q3 24 | $-837.0K | $-88.1M | ||
| Q2 24 | $-127.0K | $-92.2M | ||
| Q1 24 | $-442.0K | $-81.4M |
| Q4 25 | 91.4% | — | ||
| Q3 25 | 90.5% | — | ||
| Q2 25 | 89.8% | — | ||
| Q1 25 | 89.7% | — | ||
| Q4 24 | 91.1% | — | ||
| Q3 24 | 91.0% | — | ||
| Q2 24 | 90.5% | — | ||
| Q1 24 | 90.7% | — |
| Q4 25 | 22.5% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | -5.8% | — | ||
| Q1 25 | -7.1% | -1105.2% | ||
| Q4 24 | 8.1% | — | ||
| Q3 24 | -19.3% | — | ||
| Q2 24 | -4.6% | — | ||
| Q1 24 | -11.2% | -903.0% |
| Q4 25 | 23.4% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | -4.9% | — | ||
| Q1 25 | -6.5% | -1003.6% | ||
| Q4 24 | 8.2% | — | ||
| Q3 24 | -17.8% | — | ||
| Q2 24 | -2.7% | — | ||
| Q1 24 | -9.4% | -813.3% |
| Q4 25 | $0.08 | — | ||
| Q3 25 | $0.01 | $-0.43 | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | $-0.02 | $-0.46 | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $-0.04 | $-0.63 | ||
| Q2 24 | $-0.01 | $-0.69 | ||
| Q1 24 | $-0.02 | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.7M | $84.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $20.7M | $567.1M |
| Total Assets | $24.5M | $621.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.7M | $84.0M | ||
| Q3 25 | $7.2M | $91.6M | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $5.1M | $93.5M | ||
| Q4 24 | $4.7M | $124.3M | ||
| Q3 24 | $5.7M | $152.4M | ||
| Q2 24 | $7.3M | $134.1M | ||
| Q1 24 | $9.2M | $152.9M |
| Q4 25 | $20.7M | $567.1M | ||
| Q3 25 | $18.9M | $607.7M | ||
| Q2 25 | $18.0M | — | ||
| Q1 25 | $17.6M | $721.1M | ||
| Q4 24 | $17.7M | $777.8M | ||
| Q3 24 | $16.7M | $838.9M | ||
| Q2 24 | $17.3M | $681.7M | ||
| Q1 24 | $17.2M | $745.8M |
| Q4 25 | $24.5M | $621.3M | ||
| Q3 25 | $25.3M | $670.0M | ||
| Q2 25 | $23.1M | — | ||
| Q1 25 | $24.6M | $799.4M | ||
| Q4 24 | $20.9M | $871.3M | ||
| Q3 24 | $20.7M | $930.1M | ||
| Q2 24 | $21.9M | $772.5M | ||
| Q1 24 | $22.6M | $841.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.4M | $-235.5M |
| Free Cash FlowOCF − Capex | $2.4M | $-235.9M |
| FCF MarginFCF / Revenue | 36.0% | -3370.0% |
| Capex IntensityCapex / Revenue | 0.1% | 5.9% |
| Cash ConversionOCF / Net Profit | 1.54× | — |
| TTM Free Cash FlowTrailing 4 quarters | $4.5M | $-622.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4M | $-235.5M | ||
| Q3 25 | $-1.7M | $-62.1M | ||
| Q2 25 | $3.1M | — | ||
| Q1 25 | $750.0K | $-73.2M | ||
| Q4 24 | $-1.3M | $-249.1M | ||
| Q3 24 | $-1.1M | $-75.1M | ||
| Q2 24 | $-1.2M | $-65.8M | ||
| Q1 24 | $869.0K | $-50.3M |
| Q4 25 | $2.4M | $-235.9M | ||
| Q3 25 | $-1.8M | $-62.1M | ||
| Q2 25 | $3.1M | — | ||
| Q1 25 | $741.0K | $-73.6M | ||
| Q4 24 | $-1.3M | $-251.1M | ||
| Q3 24 | $-1.1M | $-75.3M | ||
| Q2 24 | $-1.2M | $-65.8M | ||
| Q1 24 | $860.0K | $-52.1M |
| Q4 25 | 36.0% | -3370.0% | ||
| Q3 25 | -29.2% | — | ||
| Q2 25 | 60.9% | — | ||
| Q1 25 | 15.1% | -958.4% | ||
| Q4 24 | -22.4% | — | ||
| Q3 24 | -23.1% | — | ||
| Q2 24 | -25.5% | — | ||
| Q1 24 | 18.4% | -520.7% |
| Q4 25 | 0.1% | 5.9% | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.2% | 5.0% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.2% | 17.8% |
| Q4 25 | 1.54× | — | ||
| Q3 25 | -5.99× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -2.71× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
